Researchers provided an overview of what they deem a hopeful future for spinal muscular atrophy and Duchenne muscular dystrophy. It’s been a little over a year since the FDA granted approval to ...
A new study looks at the balancing act physicians and families must carry out when managing expectations at a time of great scientific advancement in spinal muscular atrophy (SMA) and Duchenne ...
-DMD preclinical data support candidate declaration for GB703, a potential DMD gene therapy designed to broaden mutation coverage and improve muscle delivery -SMA1 preclinical data support the ongoing ...
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking ...
Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal ...
Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...
The 22-year-old Egyptian patient travelled to Dubai to receive the transformative one-time treatment at Medcare Royal Specialty Hospital for his genetic neuromuscular condition. This marks a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results